- Male and female adults 65 years of age and older.
- Determined by medical history, physical examination, and clinical judgment to be
eligible for the study.
- Expected to be available for the duration of the trial (up to approximately 13
- Received previous immunization with 23vPS.
- Serious chronic disorders including metastatic malignancy
- Known or suspected hypersensitivity to any vaccine or vaccine components